Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
IQ-AI Limited ( (GB:IQAI) ) just unveiled an announcement.
IQ-AI Limited’s subsidiary, Imaging Biometrics, has expanded its distribution agreement with Blackford Analysis, enabling the latter to sell additional IB products such as IB Nimble, IB ASL, and FTB technologies. This collaboration leverages Blackford’s extensive AI platform to enhance product accessibility and streamline healthcare workflows, thereby improving patient care, particularly in neuro-oncology and stroke management.
More about IQ-AI Limited
IQ-AI Limited, through its subsidiary Imaging Biometrics, LLC (IB), provides innovative quantitative imaging platforms and therapeutics aimed at enhancing the efficiency and effectiveness of clinical diagnoses and treatments. IB focuses on transforming healthcare delivery by offering advanced imaging solutions that support improved patient care.
YTD Price Performance: 14.29%
Average Trading Volume: 692,545
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £3.55M
Learn more about IQAI stock on TipRanks’ Stock Analysis page.